Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS

Future Virology

Volumn 4, Issue 6, 2009, Pages 605-619

  Hultquist, Judd F ^b   Harris, Reuben S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

AIDS; APOBEC3F; APOBEC3G; Coffin's razor; DNA cytidine deamination; HIV; Host pathogen interaction; Hypermutation; Hypomutation; Retrovirus restriction; Vif

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; UBIQUITIN PROTEIN LIGASE E3; VIF PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; REVIEW; VIRUS GENOME; VIRUS INHIBITION; VIRUS MUTATION; VIRUS NUCLEOCAPSID; VIRUS REPLICATION; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 73949141798     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.09.59     Document Type: Review

References (158)

1. Harris RS, Petersen-Mahrt SK, Neuberger MS: RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell. 10(5), 1247-1253 (2002). ■■ Discovery of APOBEC3G as a DNA deaminase.
2. Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418(6898), 646-650 (2002). ■■ Discovery of APOBEC3G as an HIV-1 restricition factor.
3. Lecossier D, Bouchonnet F, Clavel F, Hance AJ: Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300(5622), 1112 (2003).
4. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D: Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424(6944), 99-103 (2003). ■■ DNA deamination mechanism for retroviral restriction.
5. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L: The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424(6944), 94-98 (2003). ■■ DNA deamination mechanism for retroviral restriction.
6. Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD: Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5a. Proc. Natl Acad. Sci. USA 101(29), 10774-10779 (2004).
7. Keckesova Z, Ylinen LM, Towers GJ: The human and African green monkey TRIM5a genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc. Natl Acad. Sci. USA 101(29), 10780-10785 (2004).
8. Perron MJ, Stremlau M, Song B, Ulm W, Mulligan RC, Sodroski J: TRIM5a mediates the postentry block to N-tropic murine leukemia viruses in human cells. Proc. Natl Acad. Sci. USA 101(32), 11827-11832 (2004).
9. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J: The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature 427(6977), 848-853 (2004).
10. Yap MW, Nisole S, Lynch C, Stoye JP: Trim5α protein restricts both HIV-1 and murine leukemia virus. Proc. Natl Acad. Sci. USA 101(29), 10786-10791 (2004).
11. Neil SJ, Zang T, Bieniasz PD: Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451(7177), 425-430 (2008).
12. Van Damme N, Goff D, Katsura C et al.: The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3(4), 245-252 (2008).
13. Harris RS, Bishop KN, Sheehy AM et al.: DNA deamination mediates innate immunity to retroviral infection. Cell 113(6), 803-809 (2003). ■■ DNA deamination mechanism for retroviral restriction.
14. Mariani R, Chen D, Schröfelbauer B et al.: Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114(1), 21-31 (2003).
15. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH: Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14(15), 1392-1396 (2004). ■ Discovery of APOBEC3F as an HIV-1 restriction factor.
16. Kobayashi M, Takaori-Kondo A, Shindo K, Abudu A, Fukunaga K, Uchiyama T: APOBEC3G targets specific virus species. J. Virol. 78(15), 8238-8244 (2004).
17. Yu Q, Konig R, Pillai S et al.: Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11(5), 435-442 (2004).
18. Doehle BP, Schäfer A, Wiegand HL, Bogerd HP, Cullen BR: Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. J. Virol. 79(13), 8201-8207 (2005).
19. Lochelt M, Romen F, Bastone P et al.: The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc. Natl Acad. Sci. USA 102(22), 7982-7987 (2005).
20. Rose KM, Marin M, Kozak SL, Kabat D: Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G. AIDS Res. Hum. Retroviruses 21(7), 611-619 (2005).
21. Russell RA, Wiegand HL, Moore MD, Schäfer A, McClure MO, Cullen BR: Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors. J. Virol. 79(14), 8724-8731 (2005).
22. Abudu A, A. Takaori-Kondo, Izumi T et al.: Murine retrovirus escapes from murine APOBEC3 via two distinct novel mechanisms. Curr. Biol. 16(15), 1565-1570 (2006).
23. Dang Y, Wang X, Esselman WJ, Zheng YH: Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 80(21), 10522-10533 (2006).
24. Delebecque F, Suspené R, Calattini S et al.: Restriction of foamy viruses by APOBEC cytidine deaminases. J. Virol. 80(2), 605-614 (2006).
25. Dutko JA, Schäfer A, Kenny AE, Cullen BR, Curcio MJ: Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases. Curr. Biol. 15(7), 661-666 (2005).
26. Esnault C, Heidmann O, Delebecque F et al.: APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433(7024), 430-433 (2005).
27. Schumacher AJ, Nissley DV, Harris RS: APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc. Natl Acad. Sci. USA 102(28), 9854-9859 (2005).
28. Bogerd HP, Wiegand HL, Doehle BP, Lueders KK, Cullen BR: APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res. 34(1), 89-95 (2006).
29. Bogerd HP, Wiegand HL, Hulme AE et al.: Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proc. Natl Acad. Sci. USA 103(23), 8780-8785 (2006).
30. Chen H, Lilley CE, Yu Q et al.: APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Curr. Biol. 16(5), 480-485 (2006).
31. Chiu YL, Witkowska HE, Hall SC et al.: High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl Acad. Sci. USA 103(42), 15588-15593 (2006).
32. Esnault C, Millet J, Schwartz O, Heidmann T: Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses. Nucleic Acids Res. 34(5), 1522-1531 (2006).
33. Muckenfuss H, Hamdorf M, Held U et al.: APOBEC3 proteins inhibit human LINE-1 retrotransposition. J. Biol. Chem. 281(31), 22161-22172 (2006).
34. Stenglein MD, Harris RS: APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J. Biol. Chem. 281(25), 16837-16841 (2006).
35. Jarmuz A, Chester A, Bayliss J et al.: An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79(3), 285-296 (2002).
36. Alce TM, Popik W: APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J. Biol. Chem. 279(33), 34083-34086 (2004).
37. Luo K, Liu B, Xiao Z et al.: Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J. Virol. 78(21), 11841-11852 (2004).
38. Schäfer A, Bogerd HP, Cullen BR: Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328(2), 163-168 (2004).
39. Svarovskaia ES, Xu H, Mbisa JL et al.: Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem. 279(34), 35822-35828 (2004).
40. Khan MA, Kao S, Miyagi E et al.: Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J. Virol. 79(9), 5870-5874 (2005).
41. Burnett A, Spearman P: APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. J. Virol. 81(10), 5000-5013 (2007).
42. Bogerd HP, Cullen BR: Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation. RNA 14(6), 1228-1236 (2008).
43. Iwatani Y, Chan DS, Wang F et al.: Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35(21), 7096-7108 (2007).
44. Iwatani Y, Takeuchi H, Strebel K, Levin JG: Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J. Virol. 80(12), 5992-6002 (2006).
45. Mbisa JL, Barr R, Thomas JA et al.: Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81(13), 7099-7110 (2007).
46. Newman EN, Holmes RK, Craig HM et al.: Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15(2), 166-170 (2005).
47. Bishop KN, Holmes RK, Malim MH: Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80(17), 8450-8458 (2006).
48. Miyagi E, Opi S, Takeuchi H et al.: Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J. Virol. 81(24), 13346-13353 (2007).
49. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH: APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 4(12), e1000231 (2008).
50. Holmes RK, Malim MH, Bishop KN: APOBEC-mediated viral restriction: not simply editing? Trends Biochem. Sci. 32(3), 118-128 (2007).
51. Soros VB, Yonemoto W, Greene WC: Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog. 3(2), e15 (2007).
52. Suspené R, Sommer P, Henry M et al.: APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res. 32(8), 2421-2429 (2004).
53. Schröfelbauer B, Yu Q, Zeitlin SG, Landau NR: Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil - DNA glycosylases. J. Virol. 79(17), 10978-10987 (2005).
54. Kaiser SM, Emerman M: Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase APOBEC3G. J. Virol. 80(2), 875-882 (2006).
55. Yang B, Chen K, Zhang C, Huang S, Zhang H: Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J. Biol. Chem. 282(16), 11667-11675 (2007).
56. Schumacher AJ, Haché G, Macduff DA, Brown WL, Harris RS: The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J. Virol. 82(6), 2652-2660 (2008).
57. Liddament MT, Brown WL, Schumacher AJ, Harris RS: APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14(15), 1385-1391 (2004). ■ Discovery of APOBEC3F as an HIV-1 restriction factor.
58. Conticello SG, Thomas CJ, Petersen-Mahrt SK, Neuberger MS: Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol. 22(2), 367-377 (2005).
59. LaRue RS, Jónsson SR, Silverstein KA et al.: The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol. Biol. 9, 104 (2008).
60. Munk C, Beck T, Zielonka J et al.: Functions, structure, and read-through alternative splicing of feline APOBEC3 genes. Genome Biol. 9(3), R48 (2008).
61. Haché G, Liddament MT, Harris RS: The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 280(12), 10920-10924 (2005).
62. Navarro F, Bollman B, Chen H et al.: Complementary function of the two catalytic domains of APOBEC3G. Virology 333(2), 374-386 (2005).
63. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR: A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23(12), 2451-2458 (2004). ■ Discovery of APOBEC3F as an HIV-1 restriction factor.
64. Yu Q, Chen D, Konig R, Mariani R, Unutmaz D, Landau NR: APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J. Biol. Chem. 279(51), 53379-53386 (2004).
65. Wichroski MJ, Robb GB, Rana TM: Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog. 2(5), e41 (2006).
66. Wichroski MJ, Ichiyama K, Rana TM: Analysis of HIV-1 viral infectivity factor-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization. J. Biol. Chem. 280(9), 8387-8396 (2005).
67. Bennett RP, Presnyak V, Wedekind JE, Smith HC: Nuclear exclusion of the HIV-1 host defense factor APOBEC3G requires a novel cytoplasmic retention signal and is not dependent on RNA binding. J. Biol. Chem. 283(12), 7320-7327 (2008).
68. Stenglein MD, Matsuo H, Harris RS: Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization. J. Virol. 82(19), 9591-9599 (2008).
69. Friew YN, Boyko V, Hu WS, Pathak VK: Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA. Retrovirology 6, 56 (2009).
70. Bennett RP, Salter JD, Liu X, Wedekind JE, Smith HC: APOBEC3G subunits selfassociate via the C-terminal deaminase domain. J. Biol. Chem. 283(48), 33329-33336 (2008).
71. + T cells. Nature 435(7038), 108-114 (2005).
72. Kozak SL, Marin M, Rose KM, Bystrom C, Kabat D: The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J. Biol. Chem. 281(39), 29105-29119 (2006).
73. Gallois-Montbrun S, Kramer B, Swanson CM et al.: Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J. Virol. 81(5), 2165-2178 (2007).
74. Wang X, Dolan PT, Dang Y, Zheng YH: Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle. J. Biol. Chem. 282(3), 1585-1594 (2007).
75. Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH: RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog. 5(3), e1000330 (2009).
76. Doehle BP, Schäfer A, Cullen BR: Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339(2), 281-288 (2005).
77. Chiu YL, Greene WC: The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annu. Rev. Immunol. 26, 317-353 (2008).
78. Goila-Gaur R, Strebel K: HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5, 51 (2008).
79. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM: Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78(11), 6073-6076 (2004). ■ Discovery of APOBEC3F as an HIV-1 restriction factor.
80. Langlois MA, Beale RC, Conticello SG, Neuberger MS: Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G antiretroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res. 33(6), 1913-1923 (2005).
81. Dang Y, Siew LM, Wang X, Han Y, Lampen R, Zheng YH: Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J. Biol. Chem. 283(17), 11606-11614 (2008).
82. Harari A, Ooms M, Mulder LC, Simon V: Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J. Virol. 83(1), 295-303 (2009).
83. OhAinle M, Kerns JA, Malik HS, Emerman M: Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J. Virol. 80(8), 3853-3862 (2006).
84. + T cells. J. Virol. 75(17), 7973-7986 (2001).
85. Land AM, Ball TB, Luo M et al.: Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J. Virol. 82(16), 8172-8182 (2008).
86. Jónsson SR, LaRue RS, Stenglein MD, Fahrenkrug SC, Andresdottir V, Harris RS: The restriction of zoonotic PERV transmission by human APOBEC3G. PLoS One 2(9), e893 (2007).
87. Esnault C, Priet S, Ribet D, Heidmann O, Heidmann T: Restriction by APOBEC3 proteins of endogenous retroviruses with an extracellular life cycle: ex vivo effects and in vivo "traces" on the murine IAPE and human HERV-K elements. Retrovirology 5, 75 (2008).
88. Lee YN, Bieniasz PD: Reconstitution of an infectious human endogenous retrovirus. PLoS Pathog. 3(1), e10 (2007).
89. Lee YN, Malim MH, Bieniasz PD: Hypermutation of an ancient human retrovirus by APOBEC3G. J. Virol. 82(17), 8762-8770 (2008).
90. Low A, Okeoma CM, Lovsin N et al.: Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virology 385(2), 455-463 (2009).
91. Mikl MC, Watt IN, Lu M et al.: Mice deficient in APOBEC2 and APOBEC3. Mol. Cell. Biol. 25(16), 7270-7277 (2005).
92. Okeoma CM, Lovsin N, Peterlin BM, Ross SR: APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 445(7130), 927-930 (2007).
93. + T lymphocytes. J. Virol. 66(11), 6489-6495 (1992).
94. Strebel K, Daugherty D, Clouse K, Cohen D, Folks T, Martin MA: The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 328(6132), 728-730 (1987).
95. von Schwedler U, Song J, Aiken C, Trono D: Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J. Virol. 67(8), 4945-4955 (1993).
96. Madani N, Kabat D: An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J. Virol. 72(12), 10251-10255 (1998).
97. Simon JH, Gaddis NC, Fouchier RA, Malim MH: Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat. Med. 4(12), 1397-1400 (1998).
98. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D: Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279(9), 7792-7798 (2004).
99. Yu X, Yu Y, Liu B et al.: Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif - Cul5 - SCF complex. Science 302(5647), 1056-1060 (2003). ■ Identification of the APOBEC3G degrading Vif - E3 ligation complex.
100. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF: Selective assembly of HIV-1 Vif - Cul5-elonginB-elonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18(23), 2867-2872 (2004).
101. Conticello SG, Harris RS, Neuberger MS: The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13(22), 2009-2013 (2003).
102. Marin M, Rose KM, Kozak SL, Kabat D: HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9(11), 1398-1403 (2003).
103. Sheehy AM, Gaddis NC, Malim MH: The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9(11), 1404-1407 (2003).
104. Stopak K, de Noronha C, Yonemoto W, Greene WC: HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12(3), 591-601 (2003).
105. Kao S, Goila-Gaur R, Miyagi E et al.: Production of infectious virus and degradation of APOBEC3G are separable functional properties of human immunodeficiency virus type 1 Vif. Virology 369(2), 329-339 (2007).
106. Opi S, Kao S, Goila-Gaur R et al.: Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J. Virol. 81(15), 8236-8246 (2007).
107. Santa-Marta M, da Silva FA, Fonseca AM, Goncalves J: HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. J. Biol. Chem. 280(10), 8765-8775 (2005).
108. Goila-Gaur R, Khan MA, Miyagi E et al.: HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes. Virology 372(1), 136-146 (2008).
109. Kao S, Miyagi E, Khan MA et al.: Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology 1, 27 (2004).
110. Barraud P, Paillart JC, Marquet R, Tisne C: Advances in the structural understanding of Vif proteins. Curr. HIV Res. 6(2), 91-99 (2008).
111. Luo K, Xiao Z, Ehrlich E et al.: Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl Acad. Sci. USA 102(32), 11444-11449 (2005).
112. Mehle A, Thomas ER, Rajendran KS, Gabuzda D: A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem. 281(25), 17259-17265 (2006).
113. Xiao Z, Ehrlich E, Yu Y et al.: Assembly of HIV-1 Vif - Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 349(2), 290-299 (2006).
114. Xiao Z, Xiong Y, Zhang W et al.: Characterization of a novel cullin5 binding domain in HIV-1 Vif. J. Mol. Biol. 373(3), 541-550 (2007).
115. Kamura T, Sato S, Haque D et al.: The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, Ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 12(24), 3872-3881 (1998).
116. Mehle A, Goncalves J, Santa-Marta M et al.: Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif - Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 18(23), 2861-2866 (2004).
117. Zhang JG, Farley A, Nicholson SE et al.: The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl Acad. Sci. USA 96(5), 2071-2076 (1999).
118. Simon JH, Sheehy AM, Carpenter EA, Fouchier RA, Malim MH: Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J. Virol. 73(4), 2675-2681 (1999).
119. Stanley BJ, Ehrlich ES, Short L et al.: Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J. Virol. 82(17), 8656-8663 (2008).
120. Chen G, He Z, Wang T, Xu R, Yu XF: A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J. Virol. 83(17), 8674-8682 (2009).
121. Dang Y, Wang X, Zhou T, York IA, Zheng YH: Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. J. Virol. 83(17), 8544-8552 (2009).
122. He Z, Zhang W, Chen G, Xu R, Yu XF: Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J. Mol. Biol. 381(4), 1000-1011 (2008).
123. Mehle A, Wilson H, Zhang C et al.: Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J. Virol. 81(23), 13235-13241 (2007).
124. Russell RA, Pathak VK: Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81(15), 8201-8210 (2007).
125. Tian C, Yu X, Zhang W, Wang T, Xu R, Yu XF: Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol. 80(6), 3112-3115 (2006).
126. Marin M, Golem S, Rose KM, Kozak SL, Kabat D: Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism. J. Virol. 82(2), 987-998 (2008).
127. Zhang W, Chen G, Niewiadomska AM, Xu R, Yu XF: Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host antiviral proteins. PLoS One 3(12), e3963 (2008).
128. Fujita M, Sakurai A, Yoshida A et al.: Amino acid residues 88 and 89 in the central hydrophilic region of human immunodeficiency virus type 1 Vif are critical for viral infectivity by enhancing the steady-state expression of Vif. J. Virol. 77(2), 1626-1632 (2003).
129. Miller JH, Presnyak V, Smith HC: The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology 4, 81 (2007).
130. Yang B, Gao L, Li L et al.: Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J. Biol. Chem. 278(8), 6596-6602 (2003).
131. Yang S, Sun Y, Zhang H: The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. J. Biol. Chem. 276(7), 4889-4893 (2001).
132. Dettenhofer M, Cen S, Carlson BA, Kleiman L, Yu XF: Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J. Virol. 74(19), 8938-8945 (2000).
133. Khan MA, Aberham C, Kao S et al.: Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J. Virol. 75(16), 7252-7265 (2001).
134. Zhang H, Pomerantz RJ, Dornadula G, Sun Y: Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J. Virol. 74(18), 8252-8261 (2000).
135. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K: The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J. Virol. 77(21), 11398-11407 (2003).
136. Karczewski MK, Strebel K: Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J. Virol. 70(1), 494-507 (1996).
137. Liu H, Wu X, Newman M, Shaw GM, Hahn BH, Kappes JC: The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. J. Virol. 69(12), 7630-7638 (1995).
138. Henriet S, Mercenne G, Bernacchi S, Paillart JC, Marquet R: Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif ) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol. Mol. Biol. Rev. 73(2), 211-232 (2009).
139. Henriet S, Sinck L, Bec G, Gorelick RJ, Marquet R, Paillart JC: Vif is a RNA chaperone that could temporally regulate RNA dimerization and the early steps of HIV-1 reverse transcription. Nucleic Acids Res. 35(15), 5141-5153 (2007).
140. Virgen CA, Hatziioannou T: Antiretroviral activity and Vif sensitivity of rhesus macaque APOBEC3 proteins. J. Virol. 81(24), 13932-13937 (2007).
141. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR: A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Natl Acad. Sci. USA 101(11), 3770-3774 (2004).
142. Mangeat B, Turelli P, Liao S, Trono D: A single amino acid determinant governs the speciess-pecific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 279(15), 14481-14483 (2004).
143. Schröfelbauer B, Chen D, Landau NR: A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif ). Proc. Natl Acad. Sci. USA 101(11), 3927-3932 (2004).
144. Xu H, Svarovskaia ES, Barr R et al.: A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc. Natl Acad. Sci. USA 101(15), 5652-5657 (2004).
145. Derse D, Hill SA, Princler G, Lloyd P, Heidecker G: Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid. Proc. Natl Acad. Sci. USA 104(8), 2915-2920 (2007).
146. Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, Kleiman L: The interaction between HIV-1 Gag and APOBEC3G. J. Biol. Chem. 279(32), 33177-33184 (2004).
147. Haché G, Shindo K, Albin JS, Harris RS: Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr. Biol. 18(11), 819-824 (2008).
148. Haché G, Abbink TE, Berkhout B, Harris RS: Optimal translation initiation enables Vif-deficient human immunodeficiency virus type 1 to escape restriction by APOBEC3G. J. Virol. 83(11), 5956-5960 (2009).
149. Nathans R, Cao H, Sharova N et al.: Small-molecule inhibition of HIV-1 Vif. Nat. Biotechnol. 26(10), 1187-1192 (2008). ■■ Discovery of the first small-molecule antagonists of Vif.
150. Kidd JM, Newman TL, Tuzun E, Kaul R, Eichler EE: Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet. 3(4), e63 (2007).
151. Harris RS: Enhancing immunity to HIV through APOBEC. Nat. Biotechnol. 26(10), 1089-1090 (2008).
152. Berkhout B, de Ronde A: APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. AIDS 18(13), 1861-1863 (2004).
153. Haché G, Mansky LM, Harris RS: Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. AIDS Rev. 8(3), 148-157 (2006).
154. Jern P, Russell RA, Pathak VK, Coffin JM: Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog. 5(4), e1000367 (2009).
155. Smith RA, Loeb LA, Preston BD: Lethal mutagenesis of HIV. Virus Res. 107(2), 215-228 (2005).
156. Simon V, Zennou V, Murray D, Huang Y, Ho DD, Bieniasz PD: Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1(1), e6 (2005).
157. Di Noia JM, Neuberger MS: Molecular mechanisms of antibody somatic hypermutation. Annu. Rev. Biochem. 1-22 (2007).
158. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, Malim MH: Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 83(18), 9474-9485 (2009).